B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models
The application of chimeric antigen receptor (CAR)-T cell therapy in patients with advanced solid tumors remains a significant challenge. Simultaneously targeting antigen and the solid tumor microenvironment are two major factors that greatly impact CAR-T cell therapy outcomes. In this study, we eng...
Main Authors: | Baozhu Huang, Liqun Luo, Jun Wang, Bailin He, Rui Feng, Na Xian, Qiong Zhang, Lieping Chen, Gangxiong Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2019.1684127 |
Similar Items
-
ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft
by: Jing-e Zhou, et al.
Published: (2021-05-01) -
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
by: Susanne Hofmann, et al.
Published: (2019-02-01) -
Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
by: Ching-Yao Yang, et al.
Published: (2020-06-01) -
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
by: Le Qin, et al.
Published: (2020-06-01) -
The Chimeric Antigen Receptor Detection Toolkit
by: Yifei Hu, et al.
Published: (2020-08-01)